1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-9813, ECOG-R9813, NCCTG-RTOG-9813, RTOG-98-13, NCT00004259
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: EORTC-26981, CAN-NCIC-CE3, EORTC-22981, NCT00006353, CE3
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-18981, NCT00020839
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EDOAGL-8725-001, A5921009, NCT00068952
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C-100-21, NCT00039000
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P03267, NCT00091572
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-18032, SPRI-PO3267, NCT00101218, EUDRACT-2004-000654-23
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A3671009, NCT00257205
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BRAD-301, NCT00615186
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99103, NCI-G00-1786, NCT00005815
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and under
Sponsor: NCI
Protocol IDs: DUMC-1735-04-9R5, DUMC-1735-02-9R3, DUMC-1735-01-9R2, DUMC-1833-99-10, NCI-G00-1796, NCT00005952
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTC-9907, UCLA-0006095, NCT00006025
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NYU-9948, SPRI-NYU-9948, NCI-G00-1907, NCI-V01-1650, NCT00014105
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: FCCC-01004, NCI-G01-1981, NCT00021307
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-01088A, NCI-G01-2025, NCT00026494
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-126, NCT00050986
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ABTC-0306, NABTT-0306, NABTT-0306, NCT00085254
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 69
Sponsor: Other
Protocol IDs: EORTC-26041, EORTC-22041, EUDRACT-2004-003896-35, NCT00128700
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-04C1, NCT00275067
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-0428, NCT00362817
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9815, H6Q-MC-S008, NCT00402116
|
|
22.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-PHI-0241, VICC PHI 0241, VU-VICC-IRB-020510, NCT00512798
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 02602, NCT00667953
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CRC-PHASE-II-PH2/028
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C94-123, NCI-V95-0643
|
